Andrew Frost

Business Insights Analyst; Cardiovascular, Metabolic, Renal, and Hematological Disorders.

Specializing in NASH and Obesity

[Andrew Frost @AFrost_DRG]

Today sees the third annual #WorldObesityDay. @TBlackstock_DRG and I discuss the pros and cons of the current obesity pharmacotherapies. #obesity @DRGinsights @WorldObesity

https://t.co/WEAfxq80Y5

[Andrew Frost @AFrost_DRG]

https://t.co/1KV4bKn7Ij. Is Belviq really the "holy grail" in the fight against obesity? #obesity #belviq #CVOT

[Andrew Frost @AFrost_DRG]

https://t.co/O5XfjFhG6g June 12th saw the launch of the first international NASH day. Read DRG's discussion of the unmet needs for non-invasive diagnostics in NASH. #NASHday #NASH

[Andrew Frost @AFrost_DRG]

https://t.co/XH0nHpSnEI A snapshot of the data from DRG's recent NASH Access and Reimbursement (US) content. #NASH

[Kerri Brown @itskerribrown]

Oh! I co-authored a #hemophilia article in #Nature Reviews Drug Discovery 🤗 it published May 21. Click on the link to read my and @ggreen_DRG’s take on the hemophilia drug market: https://t.co/kKBuLGNzeC #DRG

[Gideon Heap @GideonHealth]

My take on Orexigen and the troubled weight loss drug, Contrave. $OREX $VVUS $ARNA #obesity @DRGinsights https://t.co/g5F2DW7tDU

[Andrew Frost @AFrost_DRG]

Another fascinating morning session at the #NASHCONGRESS, with 3 talks on the future of non-invasive biomarkers in NASH. Some really nice visual examples from @LiverMultiScan. #NASH

[Andrew Frost @AFrost_DRG]

"With repurposed drugs, companies can cut the time to Phase II trials from 5-10 years to 1-2 years". Could repurposed drugs be the next area of interest in NASH? #NASHCONGRESS #NASH

[Andrew Frost @AFrost_DRG]

"HCV is beautiful in its simplicity; NASH is fascinating in its complexity". Very nice talk from @Novartis at the afternoon session of the #NASHCONGRESS on the potential for combination therapies in NASH. @DRGinsights #NASH

[Andrew Frost @AFrost_DRG]

Great morning session at the #NASHCONGRESS. Fascinating talk from @EMA_News on the importance of CV outcomes in trial design for emerging NASH therapies. #NASH

[Andrew Frost @AFrost_DRG]

Next week I'll be attending the 2018 Global NASH Congress in London with @TBlackstock_DRG . Check out my preview of the event here; https://t.co/Nm3431YasC. @DRGinsights #NASH #fattyliver #liverdisease